非小细胞肺癌中的KRAS抑制剂：综述

Tang Min, Wu Yijun, Bai Xiufeng, Lu You

Division of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.

Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.

Onco Targets Ther. 2024 Aug 24;17:683-695. doi: 10.2147/OTT.S473368. eCollection 2024.

Rat sarcoma virus () GTPase is one of the most important drivers of non-small cell lung cancer (NSCLC). has three different isoforms (Harvey rat sarcoma viral oncogene homolog [, Kirsten rat sarcoma viral oncogene homolog [ and Neuroblastoma ras viral oncogene homolog []), of which is most commonly mutated in NSCLC. The mutated KRAS protein was historically thought to be "undruggable" until the development of KRAS inhibitors. In this review, from the aspect of brain metastasis, we aim to provide an overview of the advances in therapies that target KRAS, the limitations of the current treatments, and future prospects in patients with p.G12C mutant NSCLC.

大鼠肉瘤病毒（）GTP酶是非小细胞肺癌（NSCLC）最重要的驱动因素之一。有三种不同的异构体（哈维大鼠肉瘤病毒癌基因同源物[、 Kirsten大鼠肉瘤病毒癌基因同源物[和神经母细胞瘤Ras病毒癌基因同源物[]），其中在NSCLC中最常发生突变。在KRAS抑制剂研发出来之前，突变的KRAS蛋白在历史上被认为是“不可成药的”。在本综述中，我们旨在从脑转移的角度，概述针对KRAS的治疗进展、当前治疗的局限性以及携带p.G12C突变的NSCLC患者的未来前景。